PL3369429T3 - Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosa - Google Patents
Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosaInfo
- Publication number
- PL3369429T3 PL3369429T3 PL16860025T PL16860025T PL3369429T3 PL 3369429 T3 PL3369429 T3 PL 3369429T3 PL 16860025 T PL16860025 T PL 16860025T PL 16860025 T PL16860025 T PL 16860025T PL 3369429 T3 PL3369429 T3 PL 3369429T3
- Authority
- PL
- Poland
- Prior art keywords
- administered
- pharmaceutical composition
- nasal mucosa
- composition intended
- intended
- Prior art date
Links
- 210000002850 nasal mucosa Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015214481 | 2015-10-30 | ||
| EP16860025.2A EP3369429B1 (en) | 2015-10-30 | 2016-10-28 | Pharmaceutical composition intended to be administered to nasal mucosa |
| PCT/JP2016/082897 WO2017073798A1 (ja) | 2015-10-30 | 2016-10-28 | 鼻粘膜投与用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3369429T3 true PL3369429T3 (pl) | 2020-06-15 |
Family
ID=58630599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16860025T PL3369429T3 (pl) | 2015-10-30 | 2016-10-28 | Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10849978B2 (pl) |
| EP (1) | EP3369429B1 (pl) |
| JP (1) | JP6629877B2 (pl) |
| KR (1) | KR20180066071A (pl) |
| CN (1) | CN108135959B (pl) |
| AU (1) | AU2016346823A1 (pl) |
| BR (1) | BR112018005811A2 (pl) |
| CA (1) | CA2995839A1 (pl) |
| DK (1) | DK3369429T3 (pl) |
| ES (1) | ES2774128T3 (pl) |
| MX (1) | MX2018005363A (pl) |
| PL (1) | PL3369429T3 (pl) |
| PT (1) | PT3369429T (pl) |
| RU (1) | RU2725664C2 (pl) |
| TW (1) | TWI745313B (pl) |
| WO (1) | WO2017073798A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12178981B2 (en) | 2017-12-27 | 2024-12-31 | Takeda Pharmaceutical Company Limited | Drug administration method |
| EP3852723B1 (en) * | 2018-09-20 | 2025-11-05 | ACADIA Pharmaceuticals Inc. | Stable intranasal formulations of carbetocin |
| FR3088193B1 (fr) | 2018-11-13 | 2021-01-22 | Andrea Fox | Composition aqueuse, son procede de fabrication, et dispositif d’administration nasal |
| JP2023500763A (ja) * | 2019-11-04 | 2023-01-11 | フェリング ベスローテン フェンノートシャップ | 泌乳の改善のためのメロトシンの鼻腔内投与 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5142420A (en) | 1974-10-08 | 1976-04-10 | Matsushita Electric Industrial Co Ltd | Tajushingobunrihoshiki |
| JPS60123426A (ja) | 1983-12-07 | 1985-07-02 | Eisai Co Ltd | 経鼻投与用セクレチン製剤 |
| JP2734554B2 (ja) | 1988-09-12 | 1998-03-30 | 藤沢薬品工業株式会社 | インスリン様成長因子ｉの点鼻用液剤 |
| US5158761A (en) * | 1989-04-05 | 1992-10-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
| JP3705620B2 (ja) | 1994-12-28 | 2005-10-12 | 帝国臓器製薬株式会社 | 経粘膜投与用製剤 |
| US5521283A (en) * | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| TWI243687B (en) | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US9023793B2 (en) * | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| NZ581452A (en) * | 2007-06-07 | 2012-11-30 | Kyalin Bioscience Inc | Intranasal carbetocin formulations and methods for the treatment of autism |
| CA2791661C (en) * | 2010-03-02 | 2019-05-07 | The University Of Tokushima | Mucosal vaccines |
| SE536091C2 (sv) | 2011-04-14 | 2013-04-30 | Pep Tonic Medical Ab | Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter |
| JP6304744B2 (ja) * | 2013-12-20 | 2018-04-04 | 国立大学法人福井大学 | 愛着障害治療剤 |
-
2016
- 2016-10-28 BR BR112018005811-4A patent/BR112018005811A2/pt not_active IP Right Cessation
- 2016-10-28 JP JP2017547363A patent/JP6629877B2/ja active Active
- 2016-10-28 WO PCT/JP2016/082897 patent/WO2017073798A1/ja not_active Ceased
- 2016-10-28 TW TW105135103A patent/TWI745313B/zh not_active IP Right Cessation
- 2016-10-28 PL PL16860025T patent/PL3369429T3/pl unknown
- 2016-10-28 AU AU2016346823A patent/AU2016346823A1/en not_active Abandoned
- 2016-10-28 KR KR1020187009565A patent/KR20180066071A/ko not_active Withdrawn
- 2016-10-28 CA CA2995839A patent/CA2995839A1/en not_active Abandoned
- 2016-10-28 RU RU2018118986A patent/RU2725664C2/ru active
- 2016-10-28 PT PT168600252T patent/PT3369429T/pt unknown
- 2016-10-28 EP EP16860025.2A patent/EP3369429B1/en active Active
- 2016-10-28 ES ES16860025T patent/ES2774128T3/es active Active
- 2016-10-28 CN CN201680063129.4A patent/CN108135959B/zh active Active
- 2016-10-28 DK DK16860025.2T patent/DK3369429T3/da active
- 2016-10-28 MX MX2018005363A patent/MX2018005363A/es unknown
- 2016-10-28 US US15/750,378 patent/US10849978B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2995839A1 (en) | 2017-05-04 |
| RU2018118986A3 (pl) | 2020-01-15 |
| TW201729830A (zh) | 2017-09-01 |
| RU2725664C2 (ru) | 2020-07-03 |
| BR112018005811A2 (pt) | 2018-10-16 |
| CN108135959A (zh) | 2018-06-08 |
| CN108135959B (zh) | 2021-12-31 |
| WO2017073798A1 (ja) | 2017-05-04 |
| US10849978B2 (en) | 2020-12-01 |
| EP3369429B1 (en) | 2019-12-11 |
| EP3369429A4 (en) | 2018-10-31 |
| EP3369429A1 (en) | 2018-09-05 |
| HK1249856A1 (zh) | 2018-11-16 |
| AU2016346823A1 (en) | 2018-03-08 |
| PT3369429T (pt) | 2020-02-20 |
| JP6629877B2 (ja) | 2020-01-15 |
| KR20180066071A (ko) | 2018-06-18 |
| ES2774128T3 (es) | 2020-07-16 |
| JPWO2017073798A1 (ja) | 2018-05-31 |
| TWI745313B (zh) | 2021-11-11 |
| DK3369429T3 (da) | 2020-02-10 |
| US20180228902A1 (en) | 2018-08-16 |
| RU2018118986A (ru) | 2019-12-02 |
| MX2018005363A (es) | 2018-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250752A0 (en) | Device with compounds for conduction to lungs, oral mucosa and brain | |
| ZA201406233B (en) | Pharmaceutical composition and administration thereof | |
| IL246377A0 (en) | Pharmaceutical preparations for oral administration | |
| IL252893B (en) | Pharmaceutical dosage form for administration to mucous membranes | |
| EP2950809A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE ORAL TREATMENT OF DIABETES | |
| ZA201605263B (en) | Pharmaceutical composition for topical administration | |
| ZA201601656B (en) | Inhalable pharmaceutical composition | |
| IL241917B (en) | Formulations for subcutaneous administration of furosemide | |
| ZA201703562B (en) | Pharmaceutical composition for oral administration comprising taxane | |
| IL240666A0 (en) | Pharmaceutical preparations for oral administration and their uses | |
| EP3020417A4 (en) | Pharmaceutical composition for respiratory administration | |
| PT3318259T (pt) | Composição farmacêutica estável para administração oral | |
| IL239958A (en) | A chewable oral preparation and process for preparing it | |
| PL3369429T3 (pl) | Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosa | |
| PL3157506T3 (pl) | Kompozycja farmaceutyczna do podawania doustnego o maskowanym smaku | |
| EP2958593A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TRANSMUCOSAL ADMINISTRATION OF BENZODIAZEPINES | |
| SMT201900592T1 (it) | Composizione farmaceutica per l'uso nell'incremento del trofismo della mucosa nasale | |
| ZA201604100B (en) | Gastro-retentive oral pharmaceutical compositions | |
| PT3650024T (pt) | Composição farmacêutica para administração nasal compreendendo rifampicinas para tratar demência | |
| IL261929B (en) | Stable pharmaceutical preparations for topical administration and their use | |
| EP2979698A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| HK40097138A (zh) | 用於施用於粘膜的药物剂型 | |
| GB201510641D0 (en) | Inhalation device for administering sustained release drug delivery to the lungs | |
| IL240119A0 (en) | Pharmaceutical compositions for oral treatment of diabetes |